We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Clinical Evaluation of Risankizumab-rzaa in the Treatment of Plaque Psoriasis.
- Authors
Reddy, Vidhatha; Yang, Eric J; Myers, Bridget; Liao, Wilson
- Abstract
Risankizumab-rzaa (Skyrizi®; AbbVie) is a humanized IgG monoclonal antibody directed against interleukin-23p19 (IL-23p19) indicated for the treatment of moderate-to-severe psoriasis in adults who are candidates for systemic therapy or phototherapy. Four pivotal Phase III trials: UltIMMa-1, UltIMMa-2, IMMhance, and IMMvent have demonstrated efficacy and safety in patients with moderate-to-severe plaque psoriasis. This review highlights important findings from these and other clinical trials that have evaluated risankizumab. In addition, we discuss the mechanism of action, pharmacokinetics/pharmacodynamics, dosing recommendations, drug interactions, other potential indications, and ongoing clinical trials.
- Subjects
PSORIASIS; PATIENT safety; DRUG interactions; MONOCLONAL antibodies; BIOCHEMICAL mechanism of action
- Publication
Journal of Inflammation Research, 2020, Vol 13, p53
- ISSN
1178-7031
- Publication type
Article
- DOI
10.2147/JIR.S215196